search
Back to results

Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop. (PRO-DIAB-1)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
enhanced care model provided by Timkl, a home support provider
Sponsored by
timkl
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Diabetes Mellitus, Type 1 focused on measuring type 1 diabetes, diabetes distress, insulin pump, insuline closed-loop, home support provider, quality of life, disease burden, treatment satisfaction, Time in Range, Patient-Physician interactions, Pharmacist

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Be an adult (age ≥ 18 years) Have Type 1 diabetes Have been on closed-loop or insulin pump therapy for ≥ 6 months Be in moderate or high diabetes-related distress defined as a DDS2 score ≥ 6 Be able to understand and complete questionnaires in French Be affiliated to the general French Social Security system Have an e-mail address Have a cell phone number Non-inclusion criteria: Be deprived of liberty, under guardianship or curatorship Not have Internet access or a cell phone Have benefited or are already benefiting from the Enhanced Care program Participating in an interventional study on a medical device for diabetes (pump, sensors, etc.) Patients who are not regularly monitored in the investigating center proposing to include them, or who are likely to change centers or move to a different living area (pharmacy) within a year of inclusion.

Sites / Locations

  • CHU Nice - Hôpital l'Archet 2Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control arm (Standard Care)

Interventional arm (Enhanced Care)

Arm Description

these patients will continue with their current home support provider's standard care

these patients will be prescribed the enhanced care model to replace the standard care provided by their current home support provider. Patients are informed that they can return to standard care at the end of the study period (1 year), or at any time if they wish to leave the study.

Outcomes

Primary Outcome Measures

Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Compare patient-reported levels of diabetes-related distress at 12 months. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.

Secondary Outcome Measures

A.1 Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Compare patient-reported levels of diabetes-related distress at 6 months. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.
A.2 Change in the sub-scores of the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Compare the dimensions of patient-reported levels of diabetes-related distress individually at 12 months. Each question of the T1-DDS-7 reports a different dimension of diabetes-related distress. Higher sub-scores indicate higher levels of diabetes-related distress in their respective dimensions.
A.3a Evolution of the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Time-series analysis of the evolution of T1-DDS-7 scores over the course of the 12-month observation period. T1-DDS-7 is assessed quarterly. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.
A.3b Evolution of the 2-question Diabetes Distress Score (DDS2) [Comparison: Enhanced Care vs Standard Care]
Time-series analysis of the evolution of DDS2 scores over the course of the 12-month observation period. Higher scores indicate higher levels of diabetes-related distress. DDS2 is every month during which the T1-DDS-7 is not. This time series will be used to complete the time-series of T1-DDS-7 scores.
B.1a Patient overall satisfaction with services provided by the home support provider
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.1b Frequency of patients' interactions with the home support provider
Number of contacts with a representative of the home support provider during the previous month. Representatives include : nurses, psychologists, and pharmacists (intervention group only).
B.1c Satisfaction with specific aspects of the services provided by the home support provider
The following aspects of services provided were each assessed using a 5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied": Were the interactions appropriately personalized for the patient? Were the interactions of adequate quality? Did the patient feel they could trust the representative? Were the interactions of an appropriate length? Was the location of the interactions satisfactory? Was the organization of the interactions satisfactory? Was the number of the interactions satisfactory? The above Likert values may be averaged to provide an overall satisfaction score.
B.2a (Intervention group only) Number of pharmacy visits
To describe the actual intervention during the study, each visit will be reported in the online SanoWeb system. The number of pharmacy visits per patient will be counted using SanoWeb data.
B.2b (Intervention group only) Duration of pharmacy visits
The duration of pharmacy visits will be evaluated using SanoWeb data.
B.2c (Intervention group only) Description of clinical or non-clinical events impacting diabetes
During pharmacy visits, patients will have the opportunity to report clinical and non-clinical events. These events are recorded in the SanoWeb system.
B.3a Patients' Perceived Effectiveness of Patient-Physician Interactions (PEPPI questionnaire)
The PEPPI questionnaire will be used to assess patients' perceived effectiveness of their interactions with their diabetes specialist. Higher scores indicate better perceived efficacy.
B.3b Patient Assessment of Chronic Illness Care (PACIC questionnaire)
The PACIC questionnaire will be used to obtain patients' assessment of overall management. Higher scores indicate a better assessment of care.
B.3c Patient assessment of information flow and transparency
5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied"
B.3d Patient assessment of how representatives of the home support provider treat confidential information
5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied"
B.4a Specialist Physician satisfaction with the services provided by the home support provider to their patients
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.4b Specialist Physician satisfaction with quantity and pertinence information provided by the home support provider on their patients
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.5a (intervention group) Pharmacist satisfaction with the services provided by the home support provider to their patients
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.5b (intervention group) Pharmacist satisfaction with the length of interactions with patients
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.5c (intervention group) Pharmacist satisfaction with the number of interactions with patients
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
B.5d (intervention group) Pharmacist perception of the usefulness of their increased role in diabetes management
Visual Analog Score ranging from 0 to 10, with higher values indicating higher levels of perceived usefulness.
C.1 Self-reported ability to use their insulin delivery system(pump or closed loop) [Comparison: Enhanced Care vs Standard Care]
3 Visual Analog Scores ranging from 0 to 10s on pump or closed loop use : device management use of basic device functions use of advanced device functions Higher scores indicate better ability to use the device.
Physician assessment of patient's ability to use their insulin delivery system (pump or closed loop [Comparison: Enhanced Care vs Standard Care]
3 Visual Analog Scores on physician's assessment of the patient's ability to use their insulin delivery system: device management use of basic device functions use of advanced device functions Higher scores indicate better perceived ability to use the device.
C.3a Patient satisfaction with treatment as measured by the Diabetes Treatment Satisfaction Questionnaire - status (DTSQs) [Comparison: Enhanced Care vs Standard Care]
The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) is an 8-question tool widely used in routine practice. Higher scores indicate higher satisfaction with their treatment.
C.3b Patient perception of treatment burden [Comparison: Enhanced Care vs Standard Care]
The Timkl-1 questionnaire is a 9-question tool used to assess patients' treatment burden, need for an enhanced care service, and quality of life. This outcome uses the treatment burden subscore, for which higher scores indicate a greater burden.
D.1 Time in the glycemic target range [Comparison: Enhanced Care vs Standard Care]
Time in the glycemic target range (Time-in-range or TIR) is an intuitive metric that denotes the amount of time in percentage that a person's glucose level remains within the proposed target range. Using measurements from continuous or flash glucose monitoring systems, TIR is the percentage of data points between 70 and 180 mg/dL. Complementary metrics are used: Time below range (TBR) = percentage of data points < 54 mg/dL Time above range (TAR) = percentage of data points > 180 mg/dL
Percentage of glycated hemoglobin (HbA1c) [Comparison: Enhanced Care vs Standard Care]
The HbA1c test is used to evaluate a person's level of glucose control. The test shows an average of the blood sugar level over the past 90 days and represents a percentage. Higher values tend to indicate worse levels of glucose control.
E.1 Patient quality of life [Comparison: Enhanced Care vs Standard Care]
The Timkl-1 questionnaire is a 9-question tool used to assess patients' treatment burden, need for an enhanced care service, and quality of life. This outcome uses the quality of life subscore, for which higher scores indicate a better quality of life.
E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care]
(intervention group) Number and relevance of clinical or non-clinical events reported by the patient to the pharmacist Number and relevance of clinical or non-clinical events reported by patients to their specialist doctor Number and relevance of clinical or non-clinical events reported by the patient (ePRO)

Full Information

First Posted
September 1, 2023
Last Updated
September 18, 2023
Sponsor
timkl
Collaborators
Sanoia
search

1. Study Identification

Unique Protocol Identification Number
NCT06050642
Brief Title
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Acronym
PRO-DIAB-1
Official Title
PRO-DIAB-1: Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 4, 2023 (Actual)
Primary Completion Date
May 4, 2025 (Anticipated)
Study Completion Date
May 4, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
timkl
Collaborators
Sanoia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Amidst medical innovations, many Type 1 diabetes patients using advanced therapy show improved control but still suffer from diabetes-related distress. To tackle this, the investigators propose an "enhanced care" model involving healthcare providers and pharmacists. The study compares standard and enhanced care for Type 1 adults, focusing on the pharmacist's role. The main question it aims to answer is : In patients with type 1 diabetes treated with pump or closed-loop therapy, does the improved enhanced care versus conventional layout improve diabetes-related distress at 12 months? Participants will complete a monthly online questionnaire to assess their diabetes-related distress as well as their frequency of use of standard and enhanced care as well as the associated patient satisfaction.
Detailed Description
Amidst accelerating innovations in care and limited medical time, many patients with Type 1 diabetes treated by pump or closed-loop therapy appear to have improved glycaemic control, but still experience significant diabetes-related distress. The investigators therefore propose that a new form of patient care service provided by a health service provider and the patient's pharmacist, as part of the new type of care called "enhanced care", could contribute to overcoming this challenge. This study compares two different care services provided to adult patients with Type 1 diabetes (PwT1D) treated with an insulin pump or a closed-loop system, known as standard care and enhanced care, the main difference between which lies in the pharmacist's involvement in the enhanced care model. The originality of this project lies in several points: Firstly, it involves evaluating a new care model called enhanced care, which has the original feature of including the involvement of the patient's dispensing pharmacist. The role of home support providers in the psychological aspects of diabetes is poorly documented in the scientific literature. Diabetes-related distress is a well-known complication, but means of prevention remain inadequate. This study integrates live collection of patient data, by the patient. Patient experience is an innovative approach that plays an increasingly important role in the evaluation of new management approaches. In addition to patient data, this study integrates data from pharmacists and physicians. These data will be used to compare the points of view of healthcare professionals and patients, in order to gain a precise idea of the service provided by the enhanced care. In itself, this comparison could contribute to identifying and understanding the difference in the points of view of healthcare professionals and patients. While there is a wealth of literature demonstrating the value of pharmacist involvement in the care of Type 2 diabetic patients, such information is lacking for Type 1 diabetes. This study, aimed at investigating the impact of the pharmacist, specifically on the distress of patients undergoing highly technical treatment, is therefore original. Finally, the design of this pragmatic, randomized study enables real-life practices to be analyzed, while maintaining the highest possible level of evidence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
type 1 diabetes, diabetes distress, insulin pump, insuline closed-loop, home support provider, quality of life, disease burden, treatment satisfaction, Time in Range, Patient-Physician interactions, Pharmacist

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
pragmatic, randomized, prospective, multisite (national), real-life study comparing home support service models
Masking
None (Open Label)
Allocation
Randomized
Enrollment
420 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control arm (Standard Care)
Arm Type
No Intervention
Arm Description
these patients will continue with their current home support provider's standard care
Arm Title
Interventional arm (Enhanced Care)
Arm Type
Experimental
Arm Description
these patients will be prescribed the enhanced care model to replace the standard care provided by their current home support provider. Patients are informed that they can return to standard care at the end of the study period (1 year), or at any time if they wish to leave the study.
Intervention Type
Other
Intervention Name(s)
enhanced care model provided by Timkl, a home support provider
Intervention Description
A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
Primary Outcome Measure Information:
Title
Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Description
Compare patient-reported levels of diabetes-related distress at 12 months. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.
Time Frame
Baseline visit (Month 0) to Final visit (Month 12)
Secondary Outcome Measure Information:
Title
A.1 Change in the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Description
Compare patient-reported levels of diabetes-related distress at 6 months. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.
Time Frame
Baseline (Month 0) to Month 6
Title
A.2 Change in the sub-scores of the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Description
Compare the dimensions of patient-reported levels of diabetes-related distress individually at 12 months. Each question of the T1-DDS-7 reports a different dimension of diabetes-related distress. Higher sub-scores indicate higher levels of diabetes-related distress in their respective dimensions.
Time Frame
Baseline (Month 0) to Month 12
Title
A.3a Evolution of the 7-question Type-1 Diabetes Distress Score (T1-DDS-7) [Comparison: Enhanced Care vs Standard Care]
Description
Time-series analysis of the evolution of T1-DDS-7 scores over the course of the 12-month observation period. T1-DDS-7 is assessed quarterly. Higher T1-DDS-7 scores indicate higher levels of diabetes-related distress.
Time Frame
quarterly between Baseline (Month 0) and Month 12
Title
A.3b Evolution of the 2-question Diabetes Distress Score (DDS2) [Comparison: Enhanced Care vs Standard Care]
Description
Time-series analysis of the evolution of DDS2 scores over the course of the 12-month observation period. Higher scores indicate higher levels of diabetes-related distress. DDS2 is every month during which the T1-DDS-7 is not. This time series will be used to complete the time-series of T1-DDS-7 scores.
Time Frame
8 times between Baseline (Month 0) and Month 12
Title
B.1a Patient overall satisfaction with services provided by the home support provider
Description
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.1b Frequency of patients' interactions with the home support provider
Description
Number of contacts with a representative of the home support provider during the previous month. Representatives include : nurses, psychologists, and pharmacists (intervention group only).
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.1c Satisfaction with specific aspects of the services provided by the home support provider
Description
The following aspects of services provided were each assessed using a 5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied": Were the interactions appropriately personalized for the patient? Were the interactions of adequate quality? Did the patient feel they could trust the representative? Were the interactions of an appropriate length? Was the location of the interactions satisfactory? Was the organization of the interactions satisfactory? Was the number of the interactions satisfactory? The above Likert values may be averaged to provide an overall satisfaction score.
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.2a (Intervention group only) Number of pharmacy visits
Description
To describe the actual intervention during the study, each visit will be reported in the online SanoWeb system. The number of pharmacy visits per patient will be counted using SanoWeb data.
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.2b (Intervention group only) Duration of pharmacy visits
Description
The duration of pharmacy visits will be evaluated using SanoWeb data.
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.2c (Intervention group only) Description of clinical or non-clinical events impacting diabetes
Description
During pharmacy visits, patients will have the opportunity to report clinical and non-clinical events. These events are recorded in the SanoWeb system.
Time Frame
monthly between Baseline (Month 0) and Month 12
Title
B.3a Patients' Perceived Effectiveness of Patient-Physician Interactions (PEPPI questionnaire)
Description
The PEPPI questionnaire will be used to assess patients' perceived effectiveness of their interactions with their diabetes specialist. Higher scores indicate better perceived efficacy.
Time Frame
at Month 6 and at Month 12
Title
B.3b Patient Assessment of Chronic Illness Care (PACIC questionnaire)
Description
The PACIC questionnaire will be used to obtain patients' assessment of overall management. Higher scores indicate a better assessment of care.
Time Frame
at Baseline (Month 0) and at Month 12
Title
B.3c Patient assessment of information flow and transparency
Description
5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied"
Time Frame
at Month 6 and at Month 12
Title
B.3d Patient assessment of how representatives of the home support provider treat confidential information
Description
5-point Likert scale, ranging from "completely satisfied" to "completely dissatisfied"
Time Frame
at Month 6 and at Month 12
Title
B.4a Specialist Physician satisfaction with the services provided by the home support provider to their patients
Description
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
Month 12
Title
B.4b Specialist Physician satisfaction with quantity and pertinence information provided by the home support provider on their patients
Description
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
Month 12
Title
B.5a (intervention group) Pharmacist satisfaction with the services provided by the home support provider to their patients
Description
Overall satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
Month 12
Title
B.5b (intervention group) Pharmacist satisfaction with the length of interactions with patients
Description
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
Month 12
Title
B.5c (intervention group) Pharmacist satisfaction with the number of interactions with patients
Description
Satisfaction is assessed using a Visual Analog Score ranging from 0 to 10, with higher values indicating higher satisfaction.
Time Frame
Month 12
Title
B.5d (intervention group) Pharmacist perception of the usefulness of their increased role in diabetes management
Description
Visual Analog Score ranging from 0 to 10, with higher values indicating higher levels of perceived usefulness.
Time Frame
Month 12
Title
C.1 Self-reported ability to use their insulin delivery system(pump or closed loop) [Comparison: Enhanced Care vs Standard Care]
Description
3 Visual Analog Scores ranging from 0 to 10s on pump or closed loop use : device management use of basic device functions use of advanced device functions Higher scores indicate better ability to use the device.
Time Frame
monthly from Baseline (Month 0) to Month 12
Title
Physician assessment of patient's ability to use their insulin delivery system (pump or closed loop [Comparison: Enhanced Care vs Standard Care]
Description
3 Visual Analog Scores on physician's assessment of the patient's ability to use their insulin delivery system: device management use of basic device functions use of advanced device functions Higher scores indicate better perceived ability to use the device.
Time Frame
Month 12
Title
C.3a Patient satisfaction with treatment as measured by the Diabetes Treatment Satisfaction Questionnaire - status (DTSQs) [Comparison: Enhanced Care vs Standard Care]
Description
The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) is an 8-question tool widely used in routine practice. Higher scores indicate higher satisfaction with their treatment.
Time Frame
Baseline (Month 0) and at Month 12
Title
C.3b Patient perception of treatment burden [Comparison: Enhanced Care vs Standard Care]
Description
The Timkl-1 questionnaire is a 9-question tool used to assess patients' treatment burden, need for an enhanced care service, and quality of life. This outcome uses the treatment burden subscore, for which higher scores indicate a greater burden.
Time Frame
Baseline (Month 0) and at Month 12
Title
D.1 Time in the glycemic target range [Comparison: Enhanced Care vs Standard Care]
Description
Time in the glycemic target range (Time-in-range or TIR) is an intuitive metric that denotes the amount of time in percentage that a person's glucose level remains within the proposed target range. Using measurements from continuous or flash glucose monitoring systems, TIR is the percentage of data points between 70 and 180 mg/dL. Complementary metrics are used: Time below range (TBR) = percentage of data points < 54 mg/dL Time above range (TAR) = percentage of data points > 180 mg/dL
Time Frame
Month 12
Title
Percentage of glycated hemoglobin (HbA1c) [Comparison: Enhanced Care vs Standard Care]
Description
The HbA1c test is used to evaluate a person's level of glucose control. The test shows an average of the blood sugar level over the past 90 days and represents a percentage. Higher values tend to indicate worse levels of glucose control.
Time Frame
at Baseline (Month 0) and at Month 12
Title
E.1 Patient quality of life [Comparison: Enhanced Care vs Standard Care]
Description
The Timkl-1 questionnaire is a 9-question tool used to assess patients' treatment burden, need for an enhanced care service, and quality of life. This outcome uses the quality of life subscore, for which higher scores indicate a better quality of life.
Time Frame
at Baseline (Month 0) and at Month 12
Title
E.2 Number and relevance of impact that can have an impact on diabetes [Comparison: Enhanced Care vs Standard Care]
Description
(intervention group) Number and relevance of clinical or non-clinical events reported by the patient to the pharmacist Number and relevance of clinical or non-clinical events reported by patients to their specialist doctor Number and relevance of clinical or non-clinical events reported by the patient (ePRO)
Time Frame
monthly between Baseline (Month 0) and Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be an adult (age ≥ 18 years) Have Type 1 diabetes Have been on closed-loop or insulin pump therapy for ≥ 6 months Be in moderate or high diabetes-related distress defined as a DDS2 score ≥ 6 Be able to understand and complete questionnaires in French Be affiliated to the general French Social Security system Have an e-mail address Have a cell phone number Non-inclusion criteria: Be deprived of liberty, under guardianship or curatorship Not have Internet access or a cell phone Have benefited or are already benefiting from the Enhanced Care program Participating in an interventional study on a medical device for diabetes (pump, sensors, etc.) Patients who are not regularly monitored in the investigating center proposing to include them, or who are likely to change centers or move to a different living area (pharmacy) within a year of inclusion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antoine POUYET, MM
Phone
+33 4 76 52 67 49
Email
antoine.pouyet@timkl.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Naima HAMAMOUCHE, M Sc A
Phone
+33 4 84 83 00 60
Email
prodiab1@sanoia.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bruno GUERCI, MD PhD
Organizational Affiliation
CHU Nancy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gérard REACH, MD PhD
Organizational Affiliation
Université Sorbonne Paris Nord
Official's Role
Study Chair
Facility Information:
Facility Name
CHU Nice - Hôpital l'Archet 2
City
Nice
State/Province
Paca
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas CHEVALIER
Email
chevalier.n@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Nicolas CHEVALIER, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://prodiab1.sanoia.com/
Description
study portal

Learn more about this trial

Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.

We'll reach out to this number within 24 hrs